Pharma and healthcare: sector news on Monday 2 November 2026
Average tone +3.8 (positive) across 3 companies with relevant coverage, from 21 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +9.2 | 15 | Coverage was dominated by third-quarter results that beat expectations, with oncology gains and a share price jump of around 7%. |
| GSK | +8.0 | 3 | Coverage centred on an FDA approval for a GSK cancer drug and trial data presented at a major oncology conference, alongside a recap of quarterly financials. |
| Haleon | −5.7 | 3 | Coverage centred on Haleon lowering its 2026 organic revenue guidance after third-quarter growth missed expectations, partly offset by a £500m buyback. |
| Convatec | — | 0 | |
| Smith & Nephew | — | 0 |
Strongest stories in the sector
- +10.0 Quarterly results above forecasts and shares up sharply.
- +10.0 Shares up on cancer successes and better-than-expected earnings.
- +10.0 Share rise driven by cancer progress and quarterly outperformance.
- +10.0 Results presentation shows cancer drugs driving outperformance and healthy pipeline.
- +10.0 Shares surged on strong cancer drug performance.
- +10.0 Combination therapy shows improved patient survival in lung cancer.
- +9.7 Regulatory approval for a cancer drug plus supportive trial data.
- −9.3 Weaker quarterly growth than analysts hoped led to a reduced forecast.
- +9.2 Recap of quarterly revenue growth, oncology progress and planned savings.
- +7.5 Investor commentary highlights positives for the longer term.
- +7.5 Recap covers quarterly financials and a regulatory approval for a new GSK product.} ,{
- +7.0 Broker analyst recommends buying the shares.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.